Skip to content
Clinical Trials – home
Not yet recruiting

Randomized double‑blind study of bacillus clausii oral powder versus placebo for digestive symptoms in patients with PPI‑induced dysbiosis

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Long‑term use of Proton Pump Inhibitors can disturb the normal balance of bacteria in the gut, a condition known as dysbiosis. The study focuses on adults who have this imbalance and examines whether adding a probiotic powder containing bacillus clausii (commercially called Enterogermina) can improve digestive comfort compared with a harmless inactive powder.

The purpose of the study is to see if the probiotic can reduce gastrointestinal symptoms in people taking these acid‑reducing medicines. Participants are randomly assigned to receive either the probiotic or the inactive powder, without knowing which they are taking. The study lasts about seven weeks, during which participants take the assigned powder each day and complete simple symptom questionnaires at several visits.

Throughout the trial, researchers keep track of any side effects or health changes, and participants may be asked to provide small samples of stool or saliva for laboratory analysis. All information is collected confidentially to evaluate the safety and possible benefit of the probiotic treatment.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Visit (Day 0)

    On the first day after joining the study, you will attend a clinic visit where your health status is recorded and a stool, saliva, and duodenal fluid sample are collected for laboratory analysis.

    You will receive a bottle of oral powder that looks identical for either the active product Enterogermina or a placebo. The label will indicate a dose of 3 billion organisms per gram (approximately 6 billion organisms in a 2 g dose).

    You will be instructed to dissolve the powder in a small amount of water and drink it once a day, preferably at the same time each day, for the duration of the study.

  2. Step 2

    First Follow‑up and Sample Collection (Day 7)

    One week after the baseline visit, you will return to the clinic or a designated collection point to provide another set of saliva, duodenal fluid, and stool samples. These samples are used to assess changes in the gut microbiome.

    No changes to the medication routine are required at this time.

  3. Step 3

    Second Follow‑up – Symptom Questionnaire (Day 14)

    Two weeks after starting the study, you will complete the GIQLI questionnaire, which asks about digestive symptoms, physical functioning, emotional well‑being, and social activities.

    You will continue taking the study powder daily as instructed.

  4. Step 4

    Mid‑Study Assessment (Day 28)

    At the four‑week mark, you will again complete the GIQLI questionnaire and provide a new set of saliva, duodenal fluid, and stool samples.

    Blood will be drawn to measure markers such as faecal zonulin, serum diamine oxidase, calprotectin, C‑reactive protein, and vitamin B12.

    You will keep taking the study powder once daily.

  5. Step 5

    Third Follow‑up – Symptom Questionnaire (Day 35)

    One week after the mid‑study visit, you will complete another GIQLI questionnaire to track any further changes in your digestive health.

    The daily dose of the study powder remains unchanged.

  6. Step 6

    Late‑Study Sample Collection (Day 42)

    Six weeks after starting, you will provide a final set of saliva, duodenal fluid, and stool samples for microbiome analysis.

    A second blood draw will be performed to repeat the laboratory measurements taken at day 28.

  7. Step 7

    Final Symptom Assessment (Day 49)

    At the end of the 7‑week period, you will complete the last GIQLI questionnaire, which captures the overall change in your gastrointestinal symptoms and quality of life.

    You will stop taking the study powder after this visit.

  8. Step 8

    Study Completion and Safety Reporting

    After the final questionnaire, you will be asked to report any adverse events or side effects that occurred during the study.

    Any remaining study medication will be returned to the clinic, and you will receive a summary of the study procedures you completed.

Who can join the trial?

5 criteria

  • You must be older than 18 years.
  • You must be willing and able to follow all study visits and instructions.
  • You must be taking PPIs (medicines that lower stomach acid) continuously for at least 6 months.
  • You must be able to swallow a size‑00 capsule that is about 23 mm long (roughly the length of a small candy).
  • You must have ongoing digestive problems and score 68 or less on the GIQLI questionnaire, a short survey that asks how your stomach and bowel symptoms affect your daily life.

Who cannot join the trial?

10 criteria

  • Taking Enterogermina® or any other probiotic (a supplement that adds “good” bacteria) within the past 30 days.
  • Not stopping proton‑pump inhibitors (PPIs) for a wash‑out period of 36‑48 hours before swallowing the study capsule.
  • Having taken vitamin B12 supplements in the previous 60 days.
  • Participating in another clinical study with an experimental drug during the last 3 months.
  • Having a known hypersensitivity (allergic reaction) to Enterogermina®.
  • Having a serious or ongoing illness that affects major body systems such as the heart, lungs, stomach, liver, kidneys, metabolism, blood, nerves, muscles, joints, mental health, eyes, or reproductive organs, or showing signs of an acute illness (a sudden, severe condition).
  • Having a history of drug or alcohol abuse (misuse of substances).
  • Being pregnant or breast‑feeding (for women).
  • Having an MRI scan scheduled during the time you would be in the study.
  • Using medicines in the week before enrollment that can greatly change how the gut moves, such as opioids (strong painkillers), prokinetics (drugs that speed up digestion), or anticholinergics; using laxatives is allowed only if the dose does not change.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Enterogermina is an oral powder that contains live spores of the friendly bacteria Bacillus clausii. It is taken by mouth and is intended to add helpful microbes to the gut. In this study the product is being tested to see if it can improve digestive symptoms that can appear after long‑term use of proton‑pump inhibitor medicines, which may disturb the normal balance of gut bacteria. By restoring a healthier mix of gut microbes, the trial aims to find out whether participants feel less discomfort such as bloating, gas, or irregular bowel movements.

What is already known about the treatment

  • Enterogermina 6 billion CFU oral powder

    This medication is a white oral powder that is mixed with water and taken by mouth. It contains spores of the probiotic bacterium Bacillus clausii and is an approved product listed under the antidiarrheal microorganisms class (ATC A07FA). It is used to help restore a healthy balance of gut bacteria and to reduce diarrhea or dysbiosis, especially after long‑term use of proton‑pump inhibitors. The spores survive the stomach’s acid, reach the intestine, and then grow to support normal bacteria and limit harmful microbes.

  • Placebo oral powder

    This is an inert powder that looks the same as the active product and is also mixed with water and taken by mouth. It contains no active ingredients and is used only as a control in the clinical trial. It has no therapeutic purpose and does not affect the body. It is classified simply as a placebo for study comparisons.

Investigated diseases

Dysbiosis - Dysbiosis is an imbalance in the composition or function of the gut microbiota. It can develop gradually when normal microbial communities are disrupted by factors such as long‑term use of acid‑suppressing drugs, diet changes, or infections. Over time the altered microbial balance may lead to reduced diversity, overgrowth of harmful bacteria, and loss of beneficial species. These changes can affect digestion, gut barrier integrity, and immune signaling, causing symptoms that may fluctuate or worsen as the imbalance persists.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-527670-36-00Estimated enrolment72 patientsSponsorMedical University Of Graz

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.